ARCT · Insider Trading
Arcturus Therapeutics Holdings Inc. Common Stock
Every open-market purchase and sale reported by ARCT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-15 | Moncef Slaoui | Director | A | +15,000 deriv. | — |
| 2026-06-15 | Peter C Farrell | Director | A | +15,000 deriv. | — |
| 2026-06-15 | John Markels | Director | A | +15,000 deriv. | — |
| 2026-06-15 | Jing L. Marantz | Director | A | +15,000 deriv. | — |
| 2026-06-15 | Edward W Holmes | Director | A | +15,000 deriv. | — |
| 2026-06-15 | James F Barlow | Director | A | +15,000 deriv. | — |
| 2026-06-15 | Magda Marquet | Director | A | +15,000 deriv. | — |
| 2026-05-07 | Dennis Mulroy | Chief Financial Officer | A | +100,000 deriv. | — |
| 2025-12-19 | Joseph E Payne | President and CEO | A | +175,000 deriv. | — |
| 2025-12-19 | Lance Kurata | Chief Legal Officer | A | +54,000 deriv. | — |
| 2025-12-19 | Joseph Roberts | Controller | A | +10,000 deriv. | — |
| 2025-12-19 | Pad Chivukula | Chief Scientific Officer & COO | A | +54,000 deriv. | — |
| 2025-08-20 | Andy Sassine | Chief Financial Officer | Buy | +1,238 | +$20.50K |
| 2025-08-19 | Andy Sassine | Chief Financial Officer | Buy | −1,238 | −$20.50K |
| 2025-06-11 | John Markels | Director | A | +15,000 deriv. | — |
| 2025-06-11 | Peter C Farrell | Director | A | +15,000 deriv. | — |
| 2025-06-11 | Magda Marquet | Director | A | +15,000 deriv. | — |
| 2025-06-11 | Jing L. Marantz | Director | A | +15,000 deriv. | — |
| 2025-06-11 | James F Barlow | Director | A | +15,000 deriv. | — |
| 2025-06-11 | Moncef Slaoui | Director | A | +15,000 deriv. | — |
| 2025-06-11 | Edward W Holmes | Director | A | +15,000 deriv. | — |
| 2024-12-18 | Lance Kurata | Chief Legal Officer | A | +60,000 deriv. | — |
| 2024-12-18 | Joseph E Payne | President and CEO | A | +196,000 deriv. | — |
| 2024-12-18 | Pad Chivukula | Chief Scientific Officer & COO | A | +60,000 deriv. | — |
| 2024-12-18 | Andy Sassine | Chief Financial Officer | A | +60,000 deriv. | — |
| 2024-10-16 | Pad Chivukula | Chief Scientific Officer & COO | Sell | −12,000 | −$249.12K |
| 2024-06-21 | Moncef Slaoui | Director | A | +29,794 deriv. | — |
| 2024-06-18 | Jing L. Marantz | Director | M | +3,131 | — |
| 2024-06-18 | Peter C Farrell | Director | M | +3,131 | — |
| 2024-06-18 | Edward W Holmes | Director | M | +3,131 | — |
| 2024-06-18 | Magda Marquet | Director | M | +3,131 | — |
| 2024-06-18 | James F Barlow | Director | M | +3,131 | — |
| 2024-06-18 | John Markels | Director | M | +3,131 | — |
| 2024-06-14 | Andy Sassine | Chief Financial Officer | Sell | −50,000 | −$1.60M |
| 2024-06-07 | Pad Chivukula | Chief Scientific Officer & COO | Sell | −114 | −$5.13K |
| 2024-06-04 | Pad Chivukula | Chief Scientific Officer & COO | Sell | −26,000 | −$1.04M |
| 2024-03-27 | Pad Chivukula | Chief Scientific Officer & COO | Sell | −17,435 | −$610.57K |
| 2024-03-21 | Pad Chivukula | Chief Scientific Officer & COO | Sell | −8,565 | −$299.84K |
| 2023-12-19 | Pad Chivukula | Chief Scientific Officer & COO | A | +125,000 deriv. | — |
| 2023-12-19 | Andy Sassine | Chief Financial Officer | A | +75,000 deriv. | — |
| 2023-12-19 | Lance Kurata | Chief Legal Officer | A | +75,000 deriv. | — |
| 2023-12-19 | Joseph E Payne | President and CEO | A | +200,000 deriv. | — |
| 2023-12-19 | Keith C Kummerfeld | See Remarks | A | +30,000 deriv. | — |
| 2023-11-03 | Pad Chivukula | Chief Scientific Officer & COO | Sell | −5,000 | −$93.60K |
| 2023-10-04 | Pad Chivukula | Chief Scientific Officer & COO | Sell | −5,000 | −$128.06K |
| 2023-09-05 | Pad Chivukula | Chief Scientific Officer & COO | Sell | −5,000 | −$157.26K |
| 2023-08-17 | Andy Sassine | Chief Financial Officer | A | +1,223 | +$21.25K |
| 2023-08-03 | Magda Marquet | Director | A | +15,000 deriv. | — |
| 2023-08-03 | Pad Chivukula | Chief Scientific Officer & COO | Sell | −5,000 | −$174.55K |
| 2023-08-03 | John Markels | Director | A | +15,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joseph E Payne | President and CEO | 1,480,097 | $16.62M |
| Pad Chivukula | Chief Scientific Officer & COO | 435,334 | $4.89M |
| Andy Sassine | Chief Financial Officer | 221,764 | $2.49M |
| Peter C Farrell | Director | 98,696 | $1.11M |
| Magda Marquet | Director | 28,073 | $315.26K |
| James F Barlow | Director | 13,131 | $147.46K |
| Edward W Holmes | Director | 3,131 | $35.16K |
| John Markels | Director | 3,131 | $35.16K |
| Jing L. Marantz | Director | 3,131 | $35.16K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARCT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.